Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 312
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT02512562 | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers | ||
| NCT04982289 | Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis | ||
| NCT05708573 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | ||
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | ||
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | ||
| NCT00037622 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection. | ||
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants | ||
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT07413250 | Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data | ||
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT02598583 | Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | ||
| NCT02013037 | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | ||
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT03083704 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa | ||
| NCT00999336 | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab | ||
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | ||
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT02193867 | Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency | ||
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | ||
| NCT01412047 | Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study | ||
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | ||
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | ||
| NCT06291376 | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | ||
| NCT00122330 | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | ||
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | ||
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) | ||
| NCT05840055 | ACT with NMOSD Patients and Caregivers Pilot Study | ||
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study | ||
| NCT02273596 | Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | ||
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | ||
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) |
